DRD2 is known to be expressed in BC, and its antagonists demonstrate an antiproliferative effect in BC cells [28,34]; thus, the modulation of DRD2 activity by TAAR1 ligands also may be considered as a perspective approach to the treatment of this disease. Here, TAAR1 is linked to breast cancer.